Twist Bioscience (TWST) Q3 Profit Surges

Twist Bioscience (NASDAQ:TWST), a synthetic DNA manufacturer serving healthcare, research, and industrial sectors, reported its third quarter fiscal 2025 results on August 4, 2025. The most notable news was a swing to profitability, as the company achieved $0.33 in GAAP diluted earnings per share, compared to an expected loss of $0.53. This sharp improvement was partially due to a one-time gain on the sale of its Atlas Data Storage business. Revenue (GAAP) totaled $96.1 million, topping the $95.61 million analyst estimate (GAAP) and rising 18% from the prior year. The quarter demonstrated consistent customer growth, significant gross margin expansion, and improved operational efficiency, though the pace of revenue growth in synthetic biology slowed. Overall, the results suggest notable progress on profitability, margin structure, and strategic execution. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q2 2025 earnings report. Twist Bioscience specializes in synthetic DNA production, providing gene fragments, next generation sequencing (NGS) tools, and antibody discovery platforms to research, diagnostic, pharmaceutical, and agricultural customers. Its unique technology uses a silicon chip platform to miniaturize the chemical synthesis of DNA, which allows for reduced chemical usage and cost-efficient production compared to conventional well plate approaches.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool